Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the draft guidance from NICE which states that it cannot recommend the use of lenacapavir for reducing the risk of HIV; and what impact this will have on their target to end new HIV transmissions in England by 2030.

No assessment has been made. The National Institute for Health and Care Excellence (NICE) develops its guidance independently based on the evidence of clinical and cost effectiveness. NICE has not yet published final guidance on lenacapavir and is currently consulting on its draft guidance.